請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53724
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 江伯倫 | |
dc.contributor.author | Tzu-Yu Feng | en |
dc.contributor.author | 馮資喻 | zh_TW |
dc.date.accessioned | 2021-06-16T02:28:21Z | - |
dc.date.available | 2020-09-24 | |
dc.date.copyright | 2015-09-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-03 | |
dc.identifier.citation | 1. Beyer Nardi N., and L. da Silva Meirelles, Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handbook Experimental Pharmacology, 2006(174): p. 249-82.
2. Le Blanc, K., et al., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. The Lancet, 2004. 363(9419): p. 1439-1441. 3. Tse, W.T., et al., Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation, 2003. 75(3): p. 389-97. 4. Aggarwal, S. and M.F. Pittenger, Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 2005. 105(4): p. 1815-22. 5. Deng, Y., et al., Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1. Stem Cells Development, 2014. 23(17): p. 2080-92. 6. Murray, P.J. and T.A. Wynn, Protective and pathogenic functions of macrophage subsets. Nature Reviews Immunology, 2011. 11(11): p. 723-737. 7. Biswas, S.K. and A. Mantovani, Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology, 2010. 11(10): p. 889-896. 8. Maggini, J., et al., Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PloS One, 2010. 5(2): p. e9252. 9. Kim, J. and P. Hematti, Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophages. Experimental Hematology, 2009. 37(12): p. 1445-1453. 10. François, M., et al., Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Molecular Therapy, 2012. 20(1): p. 187-195. 11. Cho, D.-I., et al., Mesenchymal stem cells reciprocally regulate the M1/M2 balance in mouse bone marrow-derived macrophages. Experimental and Molecular Medicine, 2014. 46(1): p. e70. 12. Le Blanc, K. and D. Mougiakakos, Multipotent mesenchymal stromal cells and the innate immune system. Nature Reviews Immunology, 2012. 12(5): p. 383-396. 13. Spaggiari, G.M., et al., Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 2006. 107(4): p. 1484-90. 14. Sotiropoulou, P.A., et al., Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 2006. 24(1): p. 74-85. 15. Raffaghello, L., et al., Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem cells, 2008. 26(1): p. 151-162. 16. Maqbool, M., et al., Human mesenchymal stem cells protect neutrophils from serum‐deprived cell death. Cell Biology International, 2011. 35(12): p. 1247-1251. 17. Luz-Crawford, P., et al., Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. Stem Cell Research Therapy, 2013. 4(3): p. 65. 18. Bernardo, M.E. and W.E. Fibbe, Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell, 2013. 13(4): p. 392-402. 19. Uccelli, A., L. Moretta, and V. Pistoia, Mesenchymal stem cells in health and disease. Nature Reviews Immunology, 2008. 8(9): p. 726-36. 20. Rasmusson, I., et al., Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 2003. 76(8): p. 1208-13. 21. Rasmusson, I., et al., Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. Journal of Leukocyte Biology, 2007. 82(4): p. 887-93. 22. Augello, A., et al., Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. European Journal of Immunology, 2005. 35(5): p. 1482-90. 23. Wang, Y., et al., Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nature Immunology, 2014. 15(11): p. 1009-16. 24. Glenn, J.D. and K.A. Whartenby, Mesenchymal stem cells: emerging mechanisms of immunomodulation and therapy. World Journal of Stem Cells, 2014. 6(5): p. 526. 25. Waterman, R.S., et al., A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PloS One, 2010. 5(4): p. e10088. 26. Lei, J., et al., Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity. Cellular Immunology, 2011. 271(1): p. 147-156. 27. Yao, Y., et al., Lipopolysaccharide preconditioning enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial infarction. Journal of Biomedical Science, 2009. 16(1): p. 74. 28. Wang, Y., et al., TLR4 inhibits mesenchymal stem cell (MSC) STAT3 activation and thereby exerts deleterious effects on MSC-mediated cardioprotection. PLoS One, 2010. 5(12): p. e14206. 29. Traggiai, E., et al., Bone Marrow‐derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B Cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells, 2008. 26(2): p. 562-569. 30. Sheng, H., et al., A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Research, 2008. 18(8): p. 846-857. 31. Polchert, D., et al., IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. European Journal of Immunology, 2008. 38(6): p. 1745-1755. 32. Li, W., et al., Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death and Differentiation, 2012. 19(9): p. 1505-1513. 33. English, K., et al., IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunology Letter, 2007. 110(2): p. 91-100. 34. Papadopoulou, A., et al., Mesenchymal stem cells are conditionally therapeutic in preclinical models of rheumatoid arthritis. Annuals of Rheumatic Diseases, 2012. 71(10): p. 1733-40. 35. Djouad, F., et al., Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheumatology, 2005. 52(5): p. 1595-603. 36. Ma, S., et al., Immunobiology of mesenchymal stem cells. Cell Death and Differentiation, 2014. 21(2): p. 216-25. 37. Yabluchanskiy, A., et al., Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology (Bethesda), 2013. 28(6): p. 391-403. 38. Bauvois, B., New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression. Biochimica et Biophysica Acta, 2012. 1825(1): p. 29-36. 39. Lu, L., et al., Restoration of intrahepatic regulatory T cells through MMP-9/13-dependent activation of TGF-beta is critical for immune homeostasis following acute liver injury. Journal of Molecular and Cell Biology, 2013. 5(6): p. 369-79. 40. Oriss, T.B., et al., Cutting Edge: MMP-9 inhibits IL-23p19 expression in dendritic cells by targeting membrane stem cell factor affecting lung IL-17 response. Journal of Immunology, 2014. 192(12): p. 5471-5. 41. Benson, H.L., et al., Endogenous matrix metalloproteinases 2 and 9 regulate activation of CD4+ and CD8+ T cells. American Journal of Respiratory Cell and Molecular Biology, 2011. 44(5): p. 700-8. 42. Ding, Y., et al., Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes, 2009. 58(8): p. 1797-806. 43. Yabluchanskiy A, M.Y., Iyer RP, Hall ME, Lindsey ML., Matrix metalloproteinase-9: many shades of function in cardiovascular disease. Physiology, 2013. 28: p. 391-403. 44. Arend, W.P., et al., Interleukin-1 receptor antagonist: role in biology. Annual Review of Immunology, 1998. 16(1): p. 27-55. 45. Schiff, M.H., Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2000. 59(suppl 1): p. i103-i108. 46. Scheller, J., et al., The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2011. 1813(5): p. 878-888. 47. Kishimoto, T., IL-6: from its discovery to clinical applications. International Immunology, 2010. 22(5): p. 347-352. 48. Kawka, E., et al., Regulation of chemokine CCL5 synthesis in human peritoneal fibroblasts: A key role of IFN-γ. Mediators of Inflammation, 2014. 2014. 49. Michlmayr, D. and C.S. McKimmie, Role of CXCL10 in central nervous system inflammation. International Journal of Interferon, Cytokine Mediator Research, 2014. 6: p. 1-18. 50. Bollyky, P.L., et al., CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-β. The Journal of Immunology, 2009. 183(4): p. 2232-2241. 51. Liu, T., et al., CD44 expression positively correlates with Foxp3 expression and suppressive function of CD4+ T. Biology Direct, 2009. 4: p. 40. 52. Chetty, C., et al., MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells. Cellular Signalling, 2012. 24(2): p. 549-559. 53. Redondo-Muñoz, J., et al., α4β1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood, 2008. 112(1): p. 169-178. 54. Ren, G., et al., Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Translational Medicine, 2012. 1(1): p. 51-58. 55. Krampera, M., et al., Immunological characterization of multipotent mesenchymal stromal cells—The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy, 2013. 15(9): p. 1054-1061. 56. Sakaida, I., et al., Transplantation of bone marrow cells reduces CCl4‐induced liver fibrosis in mice. Hepatology, 2004. 40(6): p. 1304-1311. 57. Dufour, A., et al., Role of matrix metalloproteinase-9 dimers in cell migration design of inhibitory peptides. Journal of Biological Chemistry, 2010. 285(46): p. 35944-35956. 58. Rincón, M., et al., Interleukin (IL)-6 directs the differentiation of IL-4–producing CD4+ T cells. The Journal of Experimental Medicine, 1997. 185(3): p. 461-470. 59. Fielding, C.A., et al., Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity, 2014. 40(1): p. 40-50. 60. Ma, C.S., et al., The origins, function, and regulation of T follicular helper cells. The Journal of Experimental Medicine, 2012. 209(7): p. 1241-1253. 61. Zhou, L., et al., IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunology, 2007. 8(9): p. 967-974. 62. Acosta-Rodriguez, E.V., et al., Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells. Nature Immunology, 2007. 8(9): p. 942-949. 63. Zheng, Y., et al., Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature, 2007. 445(7128): p. 648-651. 64. Korn, T., et al., IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proceedings of the National Academy of Sciences U.S.A., 2008. 105(47): p. 18460-18465. 65. Mauer, J., et al., Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nature Immunology, 2014. 15(5): p. 423-430. 66. Farber, J.M., Mig and IP-10: CXC chemokines that target lymphocytes. Journal of Leukocyte Biology, 1997. 61(3): p. 246-257. 67. Hecht, T.T., D. Longo, and L. Matis, The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. The Journal of Immunology, 1983. 131(3): p. 1049-1055. 68. Ben-Sasson, S.Z., et al., IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proceedings of the National Academy of Sciences, 2009. 106(17): p. 7119-7124. 69. Springall, R., et al., Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease. PloS One, 2013. 8(8): p. e72291. 70. Siiskonen, H., et al., Hyaluronan synthase 1 (HAS1) produces a cytokine-and glucose-inducible, CD44-dependent cell surface coat. Experimental Cell Research, 2014. 320(1): p. 153-163. 71. Qu, C., et al., Extensive CD44-dependent hyaluronan coats on human bone marrow-derived mesenchymal stem cells produced by hyaluronan synthases HAS1, HAS2 and HAS3. The International Journal of Biochemistry and Cell Biology, 2014. 48: p. 45-54. 72. Chakraborti, S., et al., Regulation of matrix metalloproteinases: an overview. Molecular and Cellular Biochemistry, 2003. 253(1-2): p. 269-285. 73. Yu, Q. and I. Stamenkovic, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes and Development, 2000. 14(2): p. 163-176. 74. Mokbel, A.N., et al., Homing and reparative effect of intra-articular injection of autologus mesenchymal stem cells in osteoarthritic animal model. BMC Musculoskeletal Disorders, 2011. 12(1): p. 259. 75. Lee, K.B., et al., Injectable mesenchymal stem cell therapy for large cartilage defects—a porcine model. Stem Cells, 2007. 25(11): p. 2964-2971. 76. Murphy, J.M., et al., Stem cell therapy in a caprine model of osteoarthritis. Arthritis and Rheumatism, 2003. 48(12): p. 3464-3474. 77. Jo, C.H., et al., Intra‐articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof‐of‐concept clinical trial. Stem Cells, 2014. 32(5): p. 1254-1266. 78. González, M.A., et al., Treatment of experimental arthritis by inducing immune tolerance with human adipose‐derived mesenchymal stem cells. Arthritis and Rheumatism, 2009. 60(4): p. 1006-1019. 79. Lupia, E., et al., Role of tumor necrosis factor‐α and platelet‐activating factor in neoangiogenesis induced by synovial fluids of patients with rheumatoid arthritis. European Journal of Immunology, 1996. 26(8): p. 1690-1694. 80. Ahrens, D., et al., Expression of matrix metalloproteinase 9 (96‐kd gelatinase B) in human rheumatoid arthritis. Arthritis and Rheumatism, 1996. 39(9): p. 1576-1587. 81. Jovanovic, D.V., et al., Stimulation of 92‐kd gelatinase (matrix metalloproteinase 9) production by interleukin‐17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis and Rheumatism, 2000. 43(5): p. 1134-1144. 82. Itoh, T., et al., The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. The Journal of Immunology, 2002. 169(5): p. 2643-2647. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53724 | - |
dc.description.abstract | 骨髓間葉幹細胞(Mesenchymal stem cells, MSCs)為多潛能性幹細胞,具有自我更新、繁殖及分化成不同細胞的能力。因著眾多試管內及體內試驗證明間葉幹細胞具有優秀的免疫調節功能,將間葉幹細胞應用在治療免疫發炎反應失調疾病被視為相當有潛力的替代療法。然而將間葉幹細胞推展至臨床使用的過程並不順利。儘管有些人體試驗結果十分成功,但有些人體臨床試驗則顯示間葉幹細胞對發炎並無抑制功能。因此,為了間葉幹細胞的實用化,進一步探討並優化其免疫調節功能實屬必要。
近年來發現間葉幹細胞的免疫調節功能部分會被周邊發炎環境所調控。過去,本實驗室發現間葉幹細胞會分泌高量的基質金屬蛋白酶-9(Matrix metalloproteinase 9, MMP-9)這個在許多發炎疾病中皆會被高度表現的蛋白。本論文延續過去的基礎,進一步探討發炎因子刺激是否會促使間葉幹細胞表現更高量的MMP-9,以及MMP-9是否會影響間葉幹細胞表現細胞激素(Cytokine)與趨化激素(Chemokine)的功能。我們發現相較於干擾素γ (Interferon-γ, IFN-γ)刺激,經脂多醣(Lipopolysaccharide, LPS)及腫瘤壞死因子α (Tumor-necrosis factor α, TNF-α)刺激後的間葉幹細胞會表現較高量的MMP-9。並且抑制MMP-9會降低間葉幹細胞表現介白素-6(Interleukin-6, IL-6)及干擾素誘導蛋白-10(C-X-C motif chemokine 10/Interferon-γ-induced protein 10, CXCL10/IP-10)的能力。 另外,抑制T細胞增生及誘導調節性T細胞(Regulatory T cell, Treg)產生為間葉幹細胞抑制免疫反應的兩大利器。本論文亦探討經過不同發炎因子刺激後的間葉幹細胞是否會因著分泌MMP-9表現量之不同而改變其抑制T細胞增生及誘導調節性T細胞的能力。實驗結果證實MMP-9確有改變間葉幹細胞對T細胞的免疫調節功能。而抑制MMP-9會經由降低IFN-γ與介白素-1β (Interleukin-1β, IL-1β)及增加CD44在T細胞的表現量,因而增加間葉幹細胞對T 細胞的抑制功能及誘導調節性T細胞產生的能力。 | zh_TW |
dc.description.abstract | Bone marrow-derived mesenchymal stem cells (MSC) possess pluripotent and self-renewal properties. Importantly, MSC exhibit potent immunomodulatory abilities both in vitro and in vivo. Based on these findings, transplantation of MSC is considered as a promising therapy for several inflammatory diseases. However, several clinical trials have demonstrated conflicting results. To realize the potential of MSC therapy, it is necessary to investigate the approaches to optimize MSC immunomodulation.
Recently, several studies indicate that the immunomodulatory abilities of MSC are partially changed by inflammatory stimuli. In our previous study, MMP-9 was highly expressed by MSC. Based on these information, this study aimed to examine that inflammatory mediators stimulation would change the MMP-9 expression in MSC or not. Then, we also investigated the role of MSCs-derived MMP-9 in the cytokines and chemkines production process. The results showed that lipopolysaccharide (LPS)-primed and Tumor-necrosis factor α (TNF-α)-primed MSC (MSC1 and MSCα) expressed higher MMP-9 than interferon-γ (IFN-γ)-primed MSC (MSCγ). Furthermore, blockade MMP-9 significantly reduced the levels of Interleukin-6 (IL-6) and C-X-C motif chemokine 10/Interferon-γ-induced protein 10 (CXCL10/IP-10) in MSCs. Suppression of T cells proliferation and induction of regulatory T cells (Treg) are two important mechanism underlying the MSC immunomodulation. We also investigated the influences of MMP-9 on these two important functions of MSC. In this section, we found that inhibition of MMP-9 significantly improved the ability of MSC1 and MSCα to suppress T cells proliferation and induce Treg. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:28:21Z (GMT). No. of bitstreams: 1 ntu-104-R02449002-1.pdf: 7821481 bytes, checksum: 1da8f6d7ecf6ae738e9905e28add235d (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Contents
Contents I Contents of Figures IV 中文摘要 1 Abstract 2 Introduction 4 1. Properties of mesenchymal stem cells 6 1.1 Definition of mesenchymal stem cells 6 1.2 The influences of MSCs on immune system 6 1.2.1 Innate immunity 6 1.2.2 Adaptive immunity 9 1.2.3 MSCs and inflammatory environment 10 1.2.3.1 TLRs stimulation 10 1.2.3.2 Cytokine milieu 11 2. The role of matrix metalloproteinase-9 in immune system 13 3. Hypothesis and specific aims 15 Materials and Methods 16 Materials 17 1. Animals 17 2. Reagents 17 2.1 Cell culture 17 2.2 Flow cytometry 18 2.3 Differentiation assays 20 2.4 Enzyme-linked immunosorbent assay (ELISA) 20 2.5 CD3/CD28-induced splenocytes proliferation assay 22 2.6 CFSE assay 22 Methods 23 1. Cell culture 23 1.1 Isolation and culture of MSCs 23 1.2 Isolation and culture of splenocytes cells 23 2. Flow cytometry 24 3. Differentiation assays 25 4. Cell viability assay 25 5. Enzyme-linked immunosorbent assay (ELISA) 26 6. CD3/CD28-induced splenocytes proliferation assay 27 7. CFSE labeling 27 8. Statistical analysis 28 Results 29 1. Characterization of murine bone marrow-derived MSCs 30 2. Protein expression profile of MSC, MSCγ, MSC1, and MSCα 30 3. Effects of MMP-9 on IL-6 and CXCL10 production in MSCs 31 4. Influences of MMP-9 on the MSCs-mediated inhibition of T cell proliferation 32 5. Inhibition of pro-inflammatory cytokines production by inhibition of MMP-9 in MSCs-cocultured splenocytes 32 6. The role of MMP-9 in the MSCs-mediated induction of CD4+CD25hiFoxp3+ cells 33 Discussion 34 1. The effects of MMP-9 on cytokine and chemokine expression in different MSCs 35 2. The influences of MMP-9 on the capability of different MSCs to suppress T cell proliferaration 37 3. Inhibition of MMP-9 decreased the level of pro-inflammatory cytokines and increased Treg population in coculture system 38 4. Conclusion 40 5. Future works 41 References 42 Contents of Figures Figure1. Surface markers of murine bone marrow-derived mesenchymal stem cells (MSCs) 50 Figure 2. The differentiation potential of MSCs 51 Figure 3. Generation of MSCγ, MSC1, and MSCα 52 Figure 4. MSC1 and MSCα expressed higher MMP-9, interleukin-6 (IL-6), interleukin-1 receptor antagonist (IL-1Ra), CCL5 (RANTES), and CXCL10 (interferon gamma-induced protein 10, IP-10) than MSC. 53 Figure 5. Cell viability assay of MMP-9 inhibitor 1 treated MSC, MSCγ, MSC1, and MSCα 54 Figure 6. Inhibition of MMP-9 significantly decreased levels of IL-6 and CXCL10 55 Figure 7. Inhibition of MMP-9 increased the suppressive activity of MSCs 56 Figure 8. Inhibition of MMP-9 decreased IFN-γ, IL-1β, and IL-17. 58 Figure 9. Inhibition of MMP-9 increased CD4+CD25hiFoxp3+, CD44 and CD25 expression in MSCs-cocultured splenocytes 59 Figure 10. Schematic showed the role of MSCs-derived MMP-9 in immunomodulation 62 | |
dc.language.iso | en | |
dc.title | 間葉幹細胞分泌之基質金屬蛋白酶-9在其免疫調節功能之角色 | zh_TW |
dc.title | The role of mesenchymal stem cell-derived matrix metalloproteinase 9 (MMP-9) in immunomodulation | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 朱清良,林泰元 | |
dc.subject.keyword | 間葉幹細胞,基質金屬蛋白?-9, | zh_TW |
dc.subject.keyword | Mesenchymal stem cell,matrix metalloproteinase 9, | en |
dc.relation.page | 62 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-03 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 免疫學研究所 | zh_TW |
顯示於系所單位: | 免疫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 7.64 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。